Study of AT-752 in Patients With Dengue Infection

Summary

The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population. The study will be conducted in several dosing cohorts to enable dose selection for subsequent trials

Timeline

Start

2022-04-29

Primary completion

2023-01-19

Completion

2023-01-19

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to deprioritize the dengue program”

Drugs

Indications